Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

ction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact: Investor Relations, Ampio Pharmaceuticals, Inc., 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Datameer announced today that ... data discovery on their big data platform. Datameer ... they need to quickly and easily visualize and ... A Fortune 19 company, Cardinal Health is one ... provides pharmaceuticals and medical products to more than ...
(Date:5/23/2013)... May 23, 2013  Omeros Corporation (NASDAQ: ... New Drug Application (IND) to evaluate OMS824 in ... Food and Drug Administration (FDA). OMS824 selectively inhibits ... of the brain linked to a wide range ... and schizophrenia. OMS824 has shown promising results in ...
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
Breaking Medicine Technology:Cardinal Health Selects Datameer for Healthcare Data Discovery 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3
... Horror stories related to medical equipment for new construction or ... of dollars are wasted, and delays in go-live dates can ... an independent nonprofit that researches the best approaches to improving ... 6 best practices to ensure a better outcome in a ...
... Oct. 28 DUSA Pharmaceuticals, Inc.® (Nasdaq GM: ... announced today that global sales volumes of the ... Photodynamic Therapy (PDT) technology platform, surpassed one million ... that dermatologists in the U.S. and abroad continue ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
(Date:5/23/2013)... 24, 2013 Magnatag’s new magnetic 365-Day ... and reduces vacation conflicts. A Manufacturing Manager from Augusta ... conflicts; now employees and managers can check the board ... Attendance is important to us and the board makes ... may seem harsh but it has made a difference.” ...
(Date:5/23/2013)... Over the past decade, the traditional ... has affected the Medical Group Practice Management industry ... hours, more young physicians are opting out of private ... says IBISWorld industry analyst Anna Son. In addition, “faced ... of older physicians are selling their practices and moving ...
(Date:5/23/2013)... 2013 Sublime Beauty® is introducing ... line, with a 35% discount through May ... two proprietary products, the Cellulite Whisperer® Gel ... Purchasers receive a report "Getting Control of Your ... a wonderful grapefruit scent," says Kathy Heshelow, founder ...
(Date:5/23/2013)... Magic often happens unexpectedly. "Howie Goes to ... twin five-year olds, Howie and his sister Heather, at ... in point. May 23, 2013 marks the debut of ... with the start of the Resort's "WeTime/MeTime” program, ... amenities and, most precious of all, opportunities for children and ...
(Date:5/23/2013)... High blood glucose is associated with poor outcomes in ... to control hyperglycemia is a common practice in hospitals. ... benefit and even shows harms associated with the use ... (ACP) Clinical Guidelines Committee in a new evidence-based paper ... Medical Quality . , "Clinicians caring for hospitalized patients ...
Breaking Medicine News(10 mins):Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2
... Feb. 13 Valentine,s Day is,not just for lovers. ... St. Valentine, takes on greater meaning when you consider ... common neurological condition that,causes seizures, and affects more than ... to the Epilepsy Foundation., Some accounts suggest St. ...
... Karen Ignagni, President,and CEO of America,s Health ... http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), "Today,s announcement presents ... root causes of rising health care costs in ... of medical services soar above inflation,every year, health ...
... study, experts caution , , WEDNESDAY, Feb. 13 (HealthDay News) ... is now being used to treat autoimmune diseases such ... a common form of multiple sclerosis. , In new ... New England Journal of Medicine , researchers reported ...
... cancer care providers from a variety of backgrounds and ... Cancer Society Lane W. Adams Quality of Life Award, ... W. Adams Quality of Life Award recognizes individuals who ... excellence in providing compassionate, skilled care, and counsel to ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... that it will release its fourth,quarter 2007 earnings ... host a conference call beginning at 10:00 a.m. ... and other corporate matters. During the,conference call the ...
... treatment options without unwanted side effects , , WEDNESDAY, Feb. ... (ALA) significantly reduced symptoms of dry eye syndrome in ... omega-3 fatty acid that,s not made by the body ... which affects about 10 million people in the United ...
Cached Medicine News:Health News:Cancer Drug Works Against MS in Early Trial 2Health News:Cancer Drug Works Against MS in Early Trial 3Health News:American Cancer Society honors exemplary cancer caregivers 2Health News:American Cancer Society honors exemplary cancer caregivers 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 20, 2008 to Discuss Fourth Quarter 2007 Results 2Health News:Drops of Fatty Acid Curb Symptoms of Dry Eye Syndrome 2
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
...
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
Medicine Products: